此前于2019年11月宣布，CABIM旨在帮助新疗法、药物和技术更快地到达患者，加强波士顿作为世界生命科学首都的地位。行业-学术界研究和开发联盟的成立是由富士胶片、哈佛大学、麻省理工学院、Cytiva（前身为GE医疗生命科学的一部分）和Alexandria Real Estate Equities,Inc.各提供同等投资，为缩短实施治疗的路径，并加速这些疗法的实际应用和商业化。该联盟将与其他合作者合作，包括Beth Israel Deaconess Medical Center、波士顿儿童医院、布莱根妇女医院、Dana-Farber癌症研究所、麻省总医院和MilliporeSigma。
该生产设施计划有8个洁净室，其配置将在其物理空间内生产细胞和病毒载体产品。该研究中心还将提供质量控制、实验室、办公室和会议室空间，从而促进该地区学术界、工业界和医院之间的合作。为扩大波士顿的专业工人基地，该中心还将专注于开发生物制药制造领域的人才管线，为新兴专业人员提供培训和课程。
富士胶片集团高级执行副总裁和首席生命科学官Takatoshi Ishikawa说：“富士胶片很高兴与领先的学术界、工业界和教学医院合作，探索基因修饰细胞疗法的应用，并为市场带来新的治疗方案。此次合作作为集团扩大医疗战略的一部分，利用富士胶片集团产品和服务的综合实力，为临床医生及其患者提供个性化的改变生活的治疗方案。”
首轮的7600万美元融资将有助于创新制造中心的建设，将支持40名全职员工，并将维持该中心的日常运营。该中心将于2022年初开始运作。
1月4日，富士胶片集团宣布在波士顿地区建立一个新的、独立的、最先进的4000万美元病毒载体和先进的治疗设施。此外，正如富士胶片集团之前所宣布的，将继续投资于其CDMO业务，扩展到包括微生物培养在内的多个领域，并且最近在细胞培养方面，投资20亿美元在美国建设大规模细胞培养生产设施。该新设施将由FUJIFILM Diosynth Biotechnologies（以下简称FDB）运营。
今后，FDB将受托开发和制造最先进的治疗药物，如CABIM正在研究和开发的基因修饰细胞治疗药物。受托制造计划在2022年春天开始。
在CABIM当中，FDB将利用在CDMO业务中积累的技术和专门知识进行受托制造，包括为建立基因修饰细胞治疗药物的批量生产技术进行生产工艺的开发，以及制造从非临床到早期临床试验的治疗药物。此外，我们还将供应集团旗下一系列包括iPS细胞、培养基、试剂等产品支持药物发现，为最先进的治疗方法的早期实用化和商业化做出贡献。
注：
CDMO：合同开发和生产组织的缩写，是指除商业药品生产外，还为制药公司提供细胞系和工艺开发、稳定性检测、临床试验药物开发和生产服务的公司。
GMP：药品生产质量管理规范
CABIM概述
名称 |
先进生物创新与生产中心，PBLLC |
地点 |
马萨诸塞州，沃特敦查尔斯市，阿森纳 |
投资方 |
学术界：哈佛大学、麻省理工学院 公司：富士胶片、Cytiva和Alexandria Real Estate Equities,Inc. （每个都有20%的同等投资） |
主要活动 |
该中心将推进细胞和基因治疗、基因编辑、免疫疗法和生物技术方面的研发。 |
Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce $76M in Funding for Manufacturing and Innovation Center
TOKYO, Jan. 14, 2021 /PRNewswire/ -- FUJIFILM Corporation (COO: Kenji Sukeno) and the Center for Advanced Biological Innovation and Manufacturing (CABIM), today announced that it has secured $76 million in financing and signed a lease for a 40,000 square-foot site in Watertown, Massachusetts at The Arsenal on the Charles, owned and operated by Alexandria Real Estate Equities, Inc. The Center will advance research and development in cell and gene therapy, gene editing, immunotherapy, and biotechnology. FUJIFILM Diosynth Biotechnologies, the Bio CDMO1 subsidiary of FUJIFILM Corporation, will provide GMP2 contract process development and manufacturing services as part of its role in the new manufacturing and innovation center.
Previously announced in November 2019, CABIM aims to help new therapeutics, medicines, and technologies reach patients faster and strengthen Greater Boston's position as the world's life science capital. The industry-academia research and development consortium was established with an equal investment each from Fujifilm, Harvard University, Massachusetts Institute of Technology, Cytiva (formerly part of GE Healthcare Life Sciences), and Alexandria Real Estate Equities, Inc. to shorten the path to implementation of therapies, and to accelerate the practical application and commercialization of these therapies. The consortium will work with other collaborators including Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, and MilliporeSigma.
The manufacturing facility is planning for eight cleanrooms, with a configuration that will produce both cell and viral vector products within its physical space. The site will also offer quality control, lab, office, and convening space to facilitate collaboration between the region's academia, industries and hospitals. The Center will also focus on developing a pipeline of talent in the field of biopharmaceutical manufacturing to expand Greater Boston's base of specialized workers, offering training and curricula to emerging professionals.
"Fujifilm is pleased to partner with leading academia, industry, and teaching hospitals, to explore the application of genetically modified cell therapies, and bring new treatment options to the market," said Takatoshi Ishikawa, senior executive vice president and chief life science officer, FUJIFILM Corporation. "This collaboration supports our larger healthcare strategy to utilize the combined strength of the Fujifilm Group's products and services to offer personalized life-altering treatment options to clinicians and their patients."
The initial $76 million fundraising round will contribute to the build of the space, support 40 full-time employees, and will maintain the Center's daily operations. The Center will commence operations in early 2022.
On January 4, FUJIFILM Corporation announced a new, separate state-of-the-art $40 Million viral vector and advanced therapy facility in the greater-Boston area. Additionally, as FUJIFILM Corporation has announced previously, the company continues to invest in growing its CDMO business across several modalities including microbial and most recently, in cell culture, with a capital investment of $2 Billion to build a large-scale cell culture manufacturing facility in the U.S. The new facilities will be operated by FUJIFILM Diosynth Biotechnologies.
1 Abbreviation for Contract Development & Manufacturing Organization which refers to companies offering services to pharmaceutical companies ranging from cell line and process development, stability testing, development and manufacturing of clinical trial drugs in addition to commercial drug manufacturing.
2 Good Manufacturing Practices
Overview of CABIM
Name |
Center for Advanced Biological Innovation and Manufacturing, PBLLC |
Location |
The Arsenal on the Charles, Watertown, Massachusetts |
Investors |
Academia：Harvard University, Massachusetts Institute of Technology Companies: Fujifilm, Cytiva and Alexandria Real Estate Equities, Inc. （each with an equal investment of 20%） |
Summary of activities |
The Center will advance research and development in cell and gene therapy, gene editing, immunotherapy, and biotechnology. |
SOURCE FUJIFILM Diosynth Biotechnologies
